Yanping Zhao

This inventor holds 25 USPTO granted patents and 11 published patent applications and 13 EPO patents, primarily in Pharmaceutical Composition. Top assignees: Beijing Tide Pharmaceutical Co., Ltd., Beijing Tide Pharmaceutical Co., Ltd.. Active years: 2019-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yanping Zhao. Retrieved from https://idiyas.com/inventor/yanping-zhao

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 25 (Patent Applications = 11)

% Patents Active = 72.0

EPO Patents = 13 (Patent Applications = 22)

Average Co-Inventor Count = 9.5

ph-index = 2

Forward Citations = 25(Granted Patents)

Company Filing History:

17 out of 18

Beijing Tide Pharmaceutical Co., Ltd.

patents

8 out of 8

Beijing Tide Pharmaceutical Co., Ltd.

patents

Years Active: 2019-2026

Loading Chart...

Areas of Expertise:

Rho-Associated Protein Kinase Inhibitor

ATR Kinase Inhibitor

P2X3 Antagonist

Pharmaceutical Composition

Hematopoietic Stem Cell Transplantation

Endometriosis Treatment

Idiopathic Pulmonary Fibrosis

Fatty Liver Disease

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12735403 - Salt of Rho-associated protein kinase inhibitor, solid form of the salt, preparation method for same, and uses thereof (2026-09-15),

2. 12702668 - Method for treating graft versus host disease caused by hematopoietic stem cell transplantation (2026-08-11),

3. 12692257 - 2,4,6-tri-substituted pyrimidine compounds as ATR kinase inhibitors (2026-07-28),

4. 12605381 - Method for treating endometriosis-associated pain by using diaminopyrimidine compound (2026-04-21),

5. 12595263 - Pyrazolopyrimidine compound used as ATR kinase inhibitor (2026-04-07),

6. 12595261 - P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition containing same, and use thereof (2026-04-07),

7. 12582653 - Method for treating idiopathic pulmonary fibrosis (2026-03-24),

8. 12544382 - 2, 4, 6-tri-substituted pyrimidine compound as ATR kinase inhibitor (2026-02-10),

9. 12509479 - P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof (2025-12-30),

10. 12485108 - Method for treating fatty liver disease and/or steatohepatitis (2025-12-02),

11. 12459917 - Salt of diaminopyrimidine compounds, and solid form thereof, preparation method therefor and use thereof (2025-11-04),

12. 12410192 - Compound for inhibiting and inducing degradation of EGFR kinase (2025-09-09),

13. 12398118 - Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and use thereof (2025-08-26),

14. 12365665 - Solid form of diaminopyrimidine compound or hydrate thereof, preparation method therefor, and application thereof (2025-07-22),

15. 12180243 - Receptor inhibitor, pharmaceutical composition comprising same, and use thereof (2024-12-31),

Title: Yanping Zhao: Innovator in Pharmaceutical Development

Introduction

Yanping Zhao is a prominent inventor based in Beijing, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific kinases involved in various diseases.

Latest Patents

Yanping Zhao holds 14 patents, showcasing his innovative work in the pharmaceutical industry. His latest patents include a compound for inhibiting and inducing degradation of EGFR kinase. This invention provides an EGFR kinase inhibitor according to a general formula and a pharmaceutical composition containing the inhibitor. The invention can be utilized to treat diseases related to EGFR kinase, such as cancer. Another notable patent is for a Rho-associated protein kinase inhibitor, which is represented by a specific formula. This patent also includes a pharmaceutical composition comprising the inhibitor and its use for preventing or treating ROCK-mediated diseases.

Career Highlights

Yanping Zhao is currently associated with Beijing Tide Pharmaceutical Co., Ltd. His work has been instrumental in advancing therapeutic options for patients suffering from various conditions.

Collaborations

Some of his notable coworkers include Hongjun Wang and Liying Zhou, who contribute to the collaborative efforts in their research and development projects.

Conclusion

Yanping Zhao's innovative work in the pharmaceutical sector highlights his commitment to improving healthcare through targeted therapies. His contributions continue to pave the way for advancements in the treatment of serious diseases.

Profile summary based on public USPTO records.